Monoclonal antibody-based therapy for neuroblastoma.
Monoclonal antibody-based therapy for neuroblastoma.
复制标题
DOI：
10.1007/s11912-000-0109-6
复制
发表时间：
2000-11-01
影响因子：
4.7
通讯作者：
Cheung, N K
中科院分区：
文献类型：
--
作者：
Cheung, N K
剂量强化联合化疗可以改善许多儿童实体瘤的临床反应。然而，治愈仍然难以捉摸。第四期成神经细胞瘤是个例外。这种成功的部分原因是基于抗体的策略，包括自体骨髓移植前自体骨髓的免疫磁性净化和针对微小残留疾病的免疫治疗。令人惊讶的是，单克隆抗体治疗，即使靶向单一抗原，即神经节苷脂G（D2），可以影响这些患者的长期无进展生存。独特型网络在肿瘤控制中的潜在作用可以在临床上加以利用。将这些抗体基因工程改造成新的形式对于更特异和有效的靶向可能性具有很大的希望，包括细胞因子和细胞的递送。临床前结果也很有希望。预计针对更广泛的儿科实体瘤的新型抗体的可用性将促进这种方法在更多患者中的成功应用。转移性神经母细胞瘤的经验为这一原则提供了证据。其他肿瘤可能会下降。
Dose-intensive combination chemotherapy can improve the clinical response of many pediatric solid tumors. However, cure remains elusive. Stage 4 neuroblastoma stands out as an exception. Part of this success is a result of antibody-based strategies, which include immunomagnetic purging of autologous marrow prior to autologous marrow transplantation and immunotherapy directed at minimal residual disease. It is striking that treatment with monoclonal antibodies, even when targeted at a single antigen, namely, ganglioside G(D2), can affect long-term progression-free survival among these patients. The potential role of the idiotype network in tumor control can be exploited clinically. The genetic engineering of these antibodies into novel forms holds great promise for more specific and effective targeting possibilities, including the delivery of cytokines and cells. Preclinical results are also promising. It is expected that the availability of novel antibodies directed at a broader spectrum of pediatric solid tumors will facilitate the successful application of this approach to more patients. Experience with metastatic neuroblastoma has provided proof of this principle. It is likely that other tumors will fall.